MoonLake Immunotherapeutics (MLTX) Institutional Ownership
13F filers reported holding 88.4% of MoonLake Immunotherapeutics (MLTX) shares as of Jun 30, 2026, across 175 filers.
4 figures withheld by our checks. Each blank figure names its reason.
- Held by 13F filers
- 88.4%
- Jun 30, 2026
- 13F filers
- 175
- quarter ended Jun 30, 2026
- 13F value
- $1.5B
- 75.2M shares
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 1,100 | $20.00 | ↗ |
| Jul 22, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 2,448 | $20.00 | ↗ |
| Jul 21, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 50,000 | $20.02 | ↗ |
| Jul 20, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 43,700 | $20.09 | ↗ |
| Jul 15, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 16,105 | $20.01 | ↗ |
| Jul 10, 2026 | Santos da Silva Jorge | Chief Executive Officer | Disposed · Open-market sale | 68,289 | $20.02 | ↗ |
| Jul 9, 2026 | Santos da Silva Jorge | Chief Executive Officer | Disposed · Open-market sale | 33,936 | $20.01 | ↗ |
| Jul 1, 2026 | Santos da Silva Jorge | Chief Executive Officer | Disposed · Open-market sale | 47,775 | $20.03 | ↗ |
| Jun 22, 2026 | Bodenstedt Matthias | Chief Financial Officer | Disposed · Open-market sale | 39,120 | $22.04 | ↗ |
| Jun 18, 2026 | Bodenstedt Matthias | Chief Financial Officer | Disposed · Open-market sale | 2,794 | $19.60 | ↗ |
| Jun 17, 2026 | BVF PARTNERS L P/IL | director | Acquired · Grant / award | 22,195Option to Buy | — | ↗ |
| Jun 17, 2026 | Bodenstedt Matthias | Chief Financial Officer | Disposed · Open-market sale | 15,082 | $19.68 | ↗ |
| Jun 17, 2026 | Phillips Andrew John | director | Acquired · Grant / award | 22,195Option to Buy | — | ↗ |
| Jun 17, 2026 | Loy Spike | director | Acquired · Grant / award | 22,195Option to Buy | — | ↗ |
| Jun 17, 2026 | Moukheibir Catherine | director | Acquired · Grant / award | 22,195Option to Buy | — | ↗ |
| Jun 17, 2026 | Xavier Ramnik | director | Acquired · Grant / award | 22,195Option to Buy | — | ↗ |
| Jun 17, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 50,000 | $19.43 | ↗ |
| Jun 16, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 50,000 | $18.70 | ↗ |
| Jun 15, 2026 | Reich Kristian | Chief Scientific Officer | Disposed · Open-market sale | 50,000 | $18.89 | ↗ |
| May 11, 2026 | Bodenstedt Matthias | Chief Financial Officer | Disposed · Open-market sale | 13,653 | $20.02 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of MoonLake Immunotherapeutics do institutions hold?
13F filers reported holding 88.4% of MoonLake Immunotherapeutics' shares as of Jun 30, 2026, across 175 filers.
How many 13F filers hold MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics was held by 175 13F filers as of Jun 30, 2026.
Not investment advice.

